{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(3)"],"submitter":["Santos Garcia D"],"pubmed_abstract":["Patients with Parkinson's disease (PD) can improve some non-motor symptoms (NMS) after starting treatment with opicapone. The aim of this study was to analyze the effectiveness of opicapone on global NMS burden in PD. OPEN-PD (Opicapone Effectiveness on Non-motor symptoms in Parkinson's Disease) is a prospective open-label single-arm study conducted in 5 centers from Spain. The primary efficacy outcome was the change from baseline (V0) to the end of the observational period (6 months ± 30 days) (V2) in the Non-Motor Symptoms Scale (NMSS) total score. Different scales were used for analyzing the change in motor, NMS, quality of life (QoL), and disability. Thirty-three patients were included between JUL/2019 and JUN/2021 (age 63.3 ± 7.91; 60.6% males; 7.48 ± 4.22 years from symptoms onset). At 6 months, 30 patients completed the follow-up (90.9%). The NMSS total score was reduced by 27.3% (from 71.67 ± 37.12 at V0 to 52.1 ± 34.76 at V2; Cohen's effect size = -0.97; p = 0.002). By domains, improvement was observed in sleep/fatigue (-40.1%; p < 0.0001), mood/apathy (-46.6%; p = 0.001), gastrointestinal symptoms (-20.7%; p = 0.029), and miscellaneous (-44.94%; p = 0.021). QoL also improved with a 18.4% reduction in the 39-item Parkinson's Disease Quality of Life Questionnaire Summary Index (from 26.67 ± 17.61 at V0 to 21.75 ± 14.9 at V2; p = 0.001). A total of 13 adverse events in 11 patients (33.3%) were reported, 1 of which was severe (not related to opicapone). Dyskinesias and nausea were the most frequent (6.1%). Opicapone is well tolerated and improves global NMS burden and QoL in PD patients at 6 months."],"journal":["Brain sciences"],"pagination":["383"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8945982"],"repository":["biostudies-literature"],"pubmed_title":["Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study."],"pmcid":["PMC8945982"],"pubmed_authors":["Oropesa-Ruiz JM","Rahim Lopez RRA","Santos Garcia D","Munoz Enriquez JG","Fernandez Pajarin G","Escamilla Sevilla F"],"additional_accession":[]},"is_claimable":false,"name":"Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.","description":"Patients with Parkinson's disease (PD) can improve some non-motor symptoms (NMS) after starting treatment with opicapone. The aim of this study was to analyze the effectiveness of opicapone on global NMS burden in PD. OPEN-PD (Opicapone Effectiveness on Non-motor symptoms in Parkinson's Disease) is a prospective open-label single-arm study conducted in 5 centers from Spain. The primary efficacy outcome was the change from baseline (V0) to the end of the observational period (6 months ± 30 days) (V2) in the Non-Motor Symptoms Scale (NMSS) total score. Different scales were used for analyzing the change in motor, NMS, quality of life (QoL), and disability. Thirty-three patients were included between JUL/2019 and JUN/2021 (age 63.3 ± 7.91; 60.6% males; 7.48 ± 4.22 years from symptoms onset). At 6 months, 30 patients completed the follow-up (90.9%). The NMSS total score was reduced by 27.3% (from 71.67 ± 37.12 at V0 to 52.1 ± 34.76 at V2; Cohen's effect size = -0.97; p = 0.002). By domains, improvement was observed in sleep/fatigue (-40.1%; p < 0.0001), mood/apathy (-46.6%; p = 0.001), gastrointestinal symptoms (-20.7%; p = 0.029), and miscellaneous (-44.94%; p = 0.021). QoL also improved with a 18.4% reduction in the 39-item Parkinson's Disease Quality of Life Questionnaire Summary Index (from 26.67 ± 17.61 at V0 to 21.75 ± 14.9 at V2; p = 0.001). A total of 13 adverse events in 11 patients (33.3%) were reported, 1 of which was severe (not related to opicapone). Dyskinesias and nausea were the most frequent (6.1%). Opicapone is well tolerated and improves global NMS burden and QoL in PD patients at 6 months.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-04-04T23:33:14.714Z","creation":"2025-04-04T23:33:14.714Z"},"accession":"S-EPMC8945982","cross_references":{"pubmed":["35326339"],"doi":["10.3390/brainsci12030383"]}}